Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAMPT | P43490 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | MMP9 | P14780 | 1/20 | 0.42 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.42 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | TP53 | P04637 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | DDOST | P39656 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | TERT | O14746 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1088243 | 0.85 | NAMPT (0.44) | NAMPTEPHX1MEN1KMT2ALMNA | |
| SCHEMBL8520214 | 0.83 | NAMPT (0.62) | NAMPTMAPK1EPHX1MEN1KMT2A | |
| SCHEMBL621278 | 0.83 | NAMPT (0.62) | NAMPTMAPK1EPHX1MEN1KMT2A | |
| SCHEMBL27549576 | 0.83 | NAMPT (0.62) | NAMPTMAPK1EPHX1MEN1KMT2A | |
| SCHEMBL25398492 | 0.83 | TSHR (0.47) | TSHRMAPK1ALDH1A1TP53MAPT | |
| SCHEMBL24003652 | 0.83 | TSHR (0.47) | TSHRMAPK1ALDH1A1TP53MAPT | |
| Hydrochloric Acid SCHEMBL29398644 | 0.81 | NAMPT (0.61) | NAMPTMAPK1EPHX1MEN1KMT2A | |
| Bromide SCHEMBL11445369 | 0.81 | NAMPT (0.61) | NAMPTMAPK1EPHX1MEN1KMT2A | |
| SCHEMBL7115295 | 0.80 | HDAC3 (0.44) | NAMPTEPHX1MEN1KMT2AMAPT | |
| SCHEMBL1723853 | 0.79 | CTSC (0.53) | MEN1KMT2ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4735111-A1 | SINGLE-DOMAIN ANTIBODY FOR INHIBITION OF NEUTROPHIL ELASTASE ACTIVITY | Université de Liège (BE) | 2026-05-06 | — | — | EP | disclosed |
| WO-2025003495-A1 | SINGLE-DOMAIN ANTIBODY FOR INHIBITION OF NEUTROPHIL ELASTASE ACTIVITY | Université de Liège (BE) | 2025-01-02 | — | — | WO | disclosed |
| WO-2011103774-A1 | PHARMACEUTICAL COMPOSITION AND USE THEREOF IN MANUFACTURING MEDICAMENTS FOR TREATING RESPIRATORY DISEASES | THE UNIVERSITY OF HONG KONG (CN) | 2011-09-01 | — | — | WO | disclosed |
| EP-0883405-B1 | AMIDINO PROTEASE INHIBITORS | DIMENSIONAL PHARM INC (US) | 2004-02-25 | — | — | EP | disclosed |
| EP-1054886-B1 | HETEROARYL AMIDINES, METHYLAMIDINES AND GUANIDINES AS PROTEASE INHIBITORS, IN PARTICULAR AS UROKINASE INHIBITORS | DIMENSIONAL PHARM INC (US) | 2002-09-04 | — | — | EP | disclosed |
| US-20010031781-A1 | Heteroaryl amidines, methylamidines and guanidines and use thereof as protease inhibitors | ILLIG CARL R (US) | 2001-10-18 | — | — | US | disclosed |
| WO-1999026920-A1 | SUBSTITUTED 3-AMINO-2-HYDROXYPHENYLACETAMIDE DERIVATIVES AS ENZYME INHIBITORS (II) | CORVAS INTERNATIONAL, INC. (US) | 1999-06-03 | — | — | WO | disclosed |
| WO-1995024207-A1 | COMPOSITION FOR THE TREATMENT OF LUNG DISEASE | MERCK & CO., INC. (US) | 1995-09-14 | — | — | WO | disclosed |
| EP-0529719-A1 | Assay for evaluating inhibition of PMN elastase by N-Substituted Azetidinones | MERCK & CO. INC. (US) | 1993-03-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010031781-A1 | Heteroaryl amidines, methylamidines and guanidines and use thereof as protease inhibitors | SERPINE1, PRSS3, PRSS2 | NAMPT 1622/4885TSHR 1131/4885MAPK1 2467/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.